Compared to other similar products in China, YpsoPen is equipped with efficient state-of-the-art delivery mechanics with gearing, fulfilling ISO 11608-1:2014 requirements for dose accuracy. This means YpsoPen will ensure patients receive the correct amount of dosage right up to the very last drop.
Under the agreement, Ypsomed's YpsoPen drug delivery platform will be developed for Beijing BKJ's glucagon-like peptide-1 (GLP-1) agonist ("Uni-E4"), a non-insulin treatment candidate; and parathyroid hormone (PTH) analogue ("Uni-PTH"), a type of agent, which are commonly used to treat diabetes and osteoporosis, respectively.
According to the statement made on Tuesday, as both treatments (Uni-E4 and Uni-PTH) require long-term administration by patients, the YpsoPen will help provide a safer self-care solution in the long run.
Upon the development of the treatments, Beijing BKJ will look after responsible for further clinical trial development and will share YpsoPen-related clinical trial information with Ypsomed.
YpsoPen is already an approved product with the Chinese National Medical Products Administration (NMPA), and is widely used with insulin-related products from the Middle Kingdom’s largest insulin producers.
"We have performed extensive market research and due diligence on the pen injector market. In the end, we chose Ypsomed's solution based on their product's reliability and market acceptance, says Kingsley Leung, chairman of Uni-Bio Science Group.
“From the beginning of our development journey of Uni-E4 and Uni-PTH, our aims were to provide patient-centric products. The integration of our products with YpsoPen not only creates a greater technological hurdle against competition, most importantly it brings more convenient administration for clinical practitioners and patients. I believe the partnership doesn't stop with YpsoPen, we hope to integrate our products in other innovative injector systems from Ypsomed, as long as they can benefit the Chinese patients,” he adds.
Uni-Bio Science Group will be the first company in China to launch GLP-1 and PTH products developed in the form of an injection pen.
